FOXO narrows Q2 loss to $0.49 EPS; capital structure streamlined, raises ~$260K in private placement

FOXO TECHNOLOGIES INC.

Basic EPS loss of $0.49 in Q2 2023 vs $3.84 loss a year ago; diluted loss $0.83 vs $6.01.
Adjusted EBITDA loss improved to $3.34M in Q2 from $8.82M in prior-year quarter; six-month loss $7.20M.
Completed two tender offers: 1.65M warrants exchanged for 7.96M shares; 4.32M shares issued to PIK note holders.
Raised ~$260K net proceeds from private placement of 5.625M shares of Class A common stock.
Launched Bioinformatics Services in July 2023; paused Longevity Report beta sales for further R&D.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FOXO TECHNOLOGIES INC. reported second quarter ended June 30, 2023 results: EPS $(0.49) and $(0.83) for the three and six months ended June 30, 2023, respectively from $(3.84) and $(6.01) for the thre.

Period: second quarter ended June 30, 2023
EPS: $(0.49) and $(0.83) for the three and six months ended June 30, 2023, respectively from $(3.84) and $(6.01) for the thre
Result: reported results

Exact text from the filing

FOXO Technologies Inc. (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, today reported financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

FOXO TECHNOLOGIES INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-065598

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.